Trevena

Revolutionary Preclinical Data Unveiled by Trevena: Potential New Direction in Neuropathic Pain and Acute Seizure Management

CHESTERBROOK, PA — Trevena, Inc. (Nasdaq: TRVN), announced key data today from two separate preclinical studies. The data provides fascinating insights into the potential effects of TRV045, a novel S1P1 …

Revolutionary Preclinical Data Unveiled by Trevena: Potential New Direction in Neuropathic Pain and Acute Seizure Management Read More

Virpax Pharmaceuticals

Virpax Pharmaceuticals Enters into CRADA with the National Advisory Neurological Disorders and Stroke Council

BERWYN, PA — Virpax®Pharmaceuticals, Inc. (NASDAQ: VRPX) recently announced that it has entered into a cooperative research and development agreement (CRADA) with the National Institute of Neurological Disorders and Stroke …

Virpax Pharmaceuticals Enters into CRADA with the National Advisory Neurological Disorders and Stroke Council Read More